News | July 02, 2024
Merck and Orion announce option providing Merck global exclusive rights to Opevesostat
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Laurus Labs receives EIR from USFDA for API facilities
Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Subscribe To Our Newsletter & Stay Updated
